2018~2022年某院新型抗肿瘤药物消化系统不良反应分析

doi:10.19803/j.1672-8629.20230204

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (11): 1273-1278.
DOI: 10.19803/j.1672-8629.20230204

2018~2022年某院新型抗肿瘤药物消化系统不良反应分析

姚鑫¹, 葛秋格¹, 李亚敏¹, 王一帆¹, 李媛媛², 刘志强^2,*

¹济源市人民医院药剂科,河南济源 459000;
²河南理工大学医学院,河南焦作 454000

收稿日期:2023-04-10 出版日期:2023-11-15 发布日期:2023-11-13
通讯作者: ^*刘志强,男,博士,副教授,医学。E-mail：zqliu@hpu.edu.cn
作者简介:姚鑫,女,硕士,主管药师,临床药学。
基金资助:
国家自然科学基金资助项目（82100745）; 河南省科技攻关计划项目（212102310642）; 河南省高校基本科研业务费专项资金资助（NSFRF210320）

Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital

YAO Xin¹, GE Qiuge¹, LI Yamin¹, WANG Yifan¹, LI Yuanyuan², LIU Zhiqiang^2,*

¹Department of Pharmacy, People’s Hospital of Jiyuan, Jiyuan Henan 459000, China;
²School of Medicine, Henan Polytechnic University, Jiaozuo Henan 454000, China

Received:2023-04-10 Online:2023-11-15 Published:2023-11-13

摘要/Abstract

摘要： 目的为新型抗肿瘤药品不良反应（ADR）监测以及针对消化系统ADR提供风险信号预警和药学监护的参考依据。方法对2018年1月1日至2022年12月31日济源市人民医院上传至国家药品不良反应监测中心的91例新型抗肿瘤药物ADR报告,按照患者年龄、性别、体重指数（BMI）、原发疾病、ADR累及系统-器官、合并用药和转归等维度进行回顾性统计分析。结果新型抗肿瘤药物ADR主要累及系统-器官为皮肤及其附属系统32例（35.16%）,消化系统20例（21.98%）;消化系统ADR临床表现以腹泻（25.00%）最为常见。多元Logistic回归方法显示消化系统ADR的独立危险因素是合并用药和低BMI,其中免疫检查点抑制剂相关消化系统ADR转归时间较长（2周~1个月）。结论临床应关注合并用药和低BMI患者的新型抗肿瘤药物ADR监测工作,针对免疫检查点抑制剂不良反应处理进行药学监护。

关键词: 新型抗肿瘤药物, 药品不良反应, 危险因素, 联合用药, 药学监护, 消化系统, 免疫检查点抑制剂

Abstract: Objective To provide data for the monitoring of adverse drug reactions (ADR) induced by new anti-tumor drugs and for early warning of danger signals and pharmaceutical monitoring of ADR. Methods Ninety-one reports of ADR of new anti-tumor drugs submitted to the National Adverse Drug Reaction Monitoring Center by Jiyuan People’s Hospital between 2018 and 2022 were retrospectively analyzed according to the patients’ age, gender, BMI, primary diseases, systems-organs involved, usage of drugs and outcomes. Results ADR of new anti-tumor drugs mainly affected the skin and its accessory systems in 32 cases (35.16%), and the digestive system in 20 cases (21.98%), with diarrhea (25.00%)as the most common type of ADR in the digestive system. Multiple logistic regression analysis showed that the independent risk factors for ADR of the digestive system were lower BMI and concomitant medication. Patients with ADR of the digestive system related to immune checkpoint inhibitors took a longer time to recover (2 weeks to 1 month). Conclusion Clinical pharmacists are to be alert to ADR of new anti-tumor drugs among patients under concomitant medication or with lower BMI and manage adverse reactions caused by immune checkpoint inhibitors.

Key words: new anti-tumor drugs, adverse drug reactions, risk factors, concomitant medication, pharmaceutical care, digestive system, immune checkpoint inhibitors

中图分类号:

姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.

YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang. Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.

参考文献

[1] HE X, WANG X, DAI HZ, et al.Analysis of the utilization of new anti-tumor drugs in the Nanjing region from 2018 to 2020[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(8): 725-730.
[2] WANG SY, WANG ZH, LI CY, et al.Progress in research on anti-tumor molecular targeted drug related diarrhea[J]. Journal of Pharmacy(药学学报), 2021, 56(12): 3377-3384.
[3] CHEN XQ, JIN YY, TANG G. New Pharmacology(新编药物学)[M]. 17th Ed, Beijing: People’s Health Publishing House, 2011: 105.
[4] National Adverse Drug Reaction Monitoring Center, National Food and Drug Administration Drug Evaluation Center. Glossary of Adverse Drug Reaction Terms (药品不良反应术语集)[M]. Beijing: China Pharmaceutical Science and Technology Press, 2003.
[5] National Health Commission. Guiding Principles for Clinical Application of Novel Antitumordrugs: 2018 Edition[EB/OL].(2018-09-21)[2023-03-10]. http://www.nhc.gov.cn/yzygj/s7659/201809/0ea15475f58a4f36b675cfa4716fa1e4.shtml.
[6] National Health Commission. Guiding Principles For Clinical Application of Novel Antitumordrugs: 2022Edition[EB/OL].(2022-12-30) [2023-03-10].http://www.nhc.gov.cn/yzygj/s7659/202212/8df034c9afb44a9d95cd986d4e12fbd8.shtml.
[7] ZHAO QL, LIN MF, CHEN J, et al.Discussion on the entry point of pharmaceutical care for lung cancer patients using new anti-tumor drugs[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(20): 2195-2197, 2202.
[8] XU WJ, GAO Y, YE ML, et al.Analysis of 346 cases of adverse reactions caused by anti-tumor drugs in a tertiary general hospital[J]. China Drug Application and Monitoring(中国药物应用与监测), 2020, 17(2): 104-107.
[9] LI YM, ZHAO ZG.Evidence based adverse reactions and pharmaceutical monitoring of ibutinib[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(7): 807-811.
[10] RUAN HB.Analysis of the use and prescription of statins for reducing blood lipid in hospitals[J]. China Practical Medicine(中国实用医药), 2017, 12(5): 147-148.
[11] HYUNA S, JACQUES F, REBECCA LS, et al.Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[12] TAI XJ, MA HF, LI J, et al.Analysis of 400 adverse reactions reports of antineoplastic drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(5): 541-544.
[13] GOMES AP, ILTER D, LOW V, et al.Age-induced accumulation of methylmalonic acid promotes tumour progression[J]. Nature, 2020(585): 283-287.
[14] ZHENG RS, ZHANG SW, ZENG HM, et al.Cancer incidence and mortality in china, 2016[J]. The Journal of the National Cancer Center, 2022, 2(1): 1-9.
[15] YANG Y, ZHOU DX, WU XL, et al.Analysis of adverse reaction reports of 84 new antitumor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(3): 334-338.
[16] CZITO BG, WILLETT CG, BENDELL JC, et al.Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase i trial results[J]. Journal of Clinical Oncology, 2006, 24: 656-662.
[17] HOPKINS AM, NQUYEN AM, KARAPETIS CS, et al.Risk factors for severe diarrhea with an afatinib treatment of non-small cell lung cancer: a pooled analysis of clinical trials[J]. Cancers (Basel), 2018, 10: 384.
[18] FAN JM, XU F.Mechanism and treatment strategies of gastrointestinal adverse reactions caused by immune checkpoint inhibitors[J]. Journal of Oncology(肿瘤学杂志), 2022, 28(2): 132-137.
[19] WU XR, YANG M.Training Materials For Reviewing Of Prescriptions By Pharmacists (药师处方审核培训教材)[M]. Beijing: China Medical Science Press, 2019.
[20] MARTHEY L, MATEUS C, MUSSINI C, et al.Cancer immunotherapy with anti-ctla-4 monoclonal antibodies induces an inflammatory bowel disease[J]. Journal of Crohn’s and Colitis, 2016, 10(4): 395-401.

2018~2022年某院新型抗肿瘤药物消化系统不良反应分析

Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.